Strategic Acquisition SaveWay Compounding Pharmacy was acquired by Myonex in April 2024, signaling an expanded clinical trial services footprint that could open collaboration and contract opportunities for sponsors and CROs seeking specialized compounding capabilities.

Sterile Compounding Niche As Delaware's only sterile compounding pharmacy, the company holds a unique market position that can be leveraged to win sterile formulation and specialty medicine contracts, appealing to clinics and hospitals requiring compliant sterile products.

Mid-market Scale With an employee base of 11–50 and revenue in the mid‑tens of millions, there is potential for scalable partnerships in regional pharma supply, specialty medications, and veterinary compounding services targeting mid-sized healthcare networks.

Vet and Human Focus The ability to supply both human and veterinarian medicines presents cross‑sell opportunities to veterinary clinics, animal health networks, and human healthcare providers seeking integrated compounding solutions.

Tech-Enabled Growth Utilize their tech stack and analytics capabilities to target prospects with digital marketing, improve supply reliability, and demonstrate data‑driven quality and compliance to win contracts with hospitals, clinics, and specialty pharmacies.